Synribo® (Omacetaxine ) CML Chronic Myeloid Leukemia
Omacetaxine mepesuccinate is a protein synthesis inhibitor that has demonstrated activity in cells harboring the T315I mutation
PUBLICATIONS
Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia
February 6, 2016, Expert Review of Hematology
Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia
February 6, 2016, Expert Review of Hematology
ARTICLES
Omacetaxine An Exciting Advance In Chronic Leukemia Care
November 11, 2021, Oncology Nursing News
Experience with Omacetaxine for TKI-Resistant TKI CML
January 26, 2017, OncLive
Landmark analysis of overall survival (OS) in patients with chronic (CP) or accelerated (AP) phase chronic myeloid leukemia (CML) treated with omacetaxine mepesuccinate
June 2, 2014, 2014 ASCO Annual Meeting
Diplomat to distribute SYNRIBO® for chronic myeloid leukemia
May 26, 2014, PBR Drug Delivery
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
February 2013, American Journal of Hematology
Omacetaxine for Chronic or Accelerated Phase CML Patients with Resistance/Intolerance to Tyrosine Kinase Inhibitors
January 15, 2013, The ASCO Post
FDA Approves Omacetaxine (Synribo®) for CML
October 26, 2012, Cancer Network
Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-Phase CML With T315I Mutation
August 15, 2012, PubLMed
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
August 15, 2012, Journal Blood
OMACETAXINE MEPESUCCINATE shows activity in CML patients who have become resistant to or intolerant of prior tyrosine kinase inhibitors (TKIs) (1,2,3)
June 1, 2012, PR Newswire
Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors
June 2012, Nature (Leukemia)
Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 35INS
May 6, 2010, Journal Blood
Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML
March 26, 2009, Phys Org
Omacetaxine An Exciting Advance In Chronic Leukemia Care
November 11, 2021, Oncology Nursing News
Experience with Omacetaxine for TKI-Resistant TKI CML
January 26, 2017, OncLive
Landmark analysis of overall survival (OS) in patients with chronic (CP) or accelerated (AP) phase chronic myeloid leukemia (CML) treated with omacetaxine mepesuccinate
June 2, 2014, 2014 ASCO Annual Meeting
Diplomat to distribute SYNRIBO® for chronic myeloid leukemia
May 26, 2014, PBR Drug Delivery
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
February 2013, American Journal of Hematology
Omacetaxine for Chronic or Accelerated Phase CML Patients with Resistance/Intolerance to Tyrosine Kinase Inhibitors
January 15, 2013, The ASCO Post
FDA Approves Omacetaxine (Synribo®) for CML
October 26, 2012, Cancer Network
Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-Phase CML With T315I Mutation
August 15, 2012, PubLMed
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
August 15, 2012, Journal Blood
OMACETAXINE MEPESUCCINATE shows activity in CML patients who have become resistant to or intolerant of prior tyrosine kinase inhibitors (TKIs) (1,2,3)
June 1, 2012, PR Newswire
Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors
June 2012, Nature (Leukemia)
Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 35INS
May 6, 2010, Journal Blood
Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML
March 26, 2009, Phys Org
See also Mutation T315I